Merck KGaA, Pfizer win another quick FDA review for avelumab; WHO tries to spur more incentives for antibiotics R&D
→ Merck KGaA and its Big Pharma partner Pfizer have won another priority review of their checkpoint inhibitor avelumab. Following up on a …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
